314 related articles for article (PubMed ID: 20132994)
1. Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis.
de Lima VM; Ikeda FA; Rossi CN; Feitosa MM; Vasconcelos RO; Nunes CM; Goto H
Vet Immunol Immunopathol; 2010 Jun; 135(3-4):296-302. PubMed ID: 20132994
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
3. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
[TBL] [Abstract][Full Text] [Related]
4. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.
Nogueira FS; Moreira MA; Borja-Cabrera GP; Santos FN; Menz I; Parra LE; Xu Z; Chu HJ; Palatnik-de-Sousa CB; Luvizotto MC
Vaccine; 2005 Sep; 23(40):4805-10. PubMed ID: 16011864
[TBL] [Abstract][Full Text] [Related]
5. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.
Saraiva EM; de Figueiredo Barbosa A; Santos FN; Borja-Cabrera GP; Nico D; Souza LO; de Oliveira Mendes-Aguiar C; de Souza EP; Fampa P; Parra LE; Menz I; Dias JG; de Oliveira SM; Palatnik-de-Sousa CB
Vaccine; 2006 Mar; 24(13):2423-31. PubMed ID: 16386824
[TBL] [Abstract][Full Text] [Related]
6. Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis.
Araújo MS; de Andrade RA; Sathler-Avelar R; Magalhães CP; Carvalho AT; Andrade MC; Campolina SS; Mello MN; Vianna LR; Mayrink W; Reis AB; Malaquias LC; Rocha LM; Martins-Filho OA
Vet Immunol Immunopathol; 2011 May; 141(1-2):64-75. PubMed ID: 21439654
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.
Saldarriaga OA; Travi BL; Park W; Perez LE; Melby PC
Vaccine; 2006 Mar; 24(11):1928-40. PubMed ID: 16310897
[TBL] [Abstract][Full Text] [Related]
8. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas.
Palatnik-de-Sousa CB; Silva-Antunes I; Morgado Ade A; Menz I; Palatnik M; Lavor C
Vaccine; 2009 Jun; 27(27):3505-12. PubMed ID: 19464528
[TBL] [Abstract][Full Text] [Related]
9. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G
Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731
[TBL] [Abstract][Full Text] [Related]
10. Canine Leishmania vaccines: still a long way to go.
Gradoni L
Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
[TBL] [Abstract][Full Text] [Related]
11. T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune.
Araújo MS; de Andrade RA; Sathler-Avelar R; Teixeira-Carvalho A; Andrade MC; Vianna LR; Mayrink W; Reis AB; Malaquias LC; Mello MN; Martins-Filho OA
Vaccine; 2009 Feb; 27(7):1008-17. PubMed ID: 19110023
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs.
Strauss-Ayali D; Baneth G; Shor S; Okano F; Jaffe CL
Int J Parasitol; 2005 Jan; 35(1):63-73. PubMed ID: 15619517
[TBL] [Abstract][Full Text] [Related]
14. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure.
Coutinho SG; Oliveira MP; Da-Cruz AM; De Luca PM; Mendonça SC; Bertho AL; Soong L; McMahon-Pratt D
Exp Parasitol; 1996 Nov; 84(2):144-55. PubMed ID: 8932764
[TBL] [Abstract][Full Text] [Related]
15. FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.
Palatnik-de-Sousa CB; Barbosa Ade F; Oliveira SM; Nico D; Bernardo RR; Santos WR; Rodrigues MM; Soares I; Borja-Cabrera GP
Expert Rev Vaccines; 2008 Aug; 7(6):833-51. PubMed ID: 18665780
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil.
Borja-Cabrera GP; Santos FN; Bauer FS; Parra LE; Menz I; Morgado AA; Soares IS; Batista LM; Palatnik-de-Sousa CB
Vaccine; 2008 Sep; 26(39):4991-7. PubMed ID: 18675868
[TBL] [Abstract][Full Text] [Related]
17. IL-6 and TNF-alpha production during active canine visceral leishmaniasis.
de Lima VM; Peiro JR; de Oliveira Vasconcelos R
Vet Immunol Immunopathol; 2007 Jan; 115(1-2):189-93. PubMed ID: 17097150
[TBL] [Abstract][Full Text] [Related]
18. Humoral immunological profile and parasitological statuses of Leishmune vaccinated and visceral leishmaniasis infected dogs from an endemic area.
de Amorim IF; Freitas E; Alves CF; Tafuri WL; Melo MN; Michalick MS; da Costa-Val AP
Vet Parasitol; 2010 Oct; 173(1-2):55-63. PubMed ID: 20638182
[TBL] [Abstract][Full Text] [Related]
19. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of anti-Leishmania (Leishmania) chagasi IgG titers detected by flow cytometry to distinguish infected from vaccinated dogs.
de Andrade RA; Reis AB; Gontijo CM; Braga LB; Rocha RD; Araújo MS; Vianna LR; Martins-Filho OA
Vet Immunol Immunopathol; 2007 Mar; 116(1-2):85-97. PubMed ID: 17287029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
